aVIDEX announces agreement with Active Biotech AB

09-Mar-2005

Avidex announced an agreement with Active Biotech AB covering the use of Avidex's monoclonal T cell receptor (mTCR) technology to help Active to develop the cancer immunotherapeutic, Anyara (TTS). Avidex's mTCR product will be used by Active for product characterisation of Anyara during its clinical development. Commercial terms were not disclosed.

Active's Anyara cancer immunotherapeutic is a fusion protein of an antibody directed against 5T4 (an antigen found on solid tumours) and a molecule derived from a bacterial superantigen that stimulates T cells to kill the tumour cell. The optimised, second generation Anyara product is in Phase I clinical trials in non-small cell lung cancer patients in the US and Norway. A similar first generation candidate immunotherapeutic has already successfully concluded Phase II trials in renal and pancreatic cancer.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance